Drugs / Gene-modified autologous stem cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03351868 | Jun 2026 → Dec 2029 expected | Fanconi anemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| — | NCT03351829 | Dec 2017 → Jan 2019 | beta thalassemia | Shenzhen Geno-Immune Medical Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gene-modified autologous stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03351829 ↗ |
| Action | Restore | “using a self-inactivating lentiviral vector to functionally correct the defective gene(s)” NCT03351829 ↗ |
| Modality | Cell therapy | “Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo” NCT03351829 ↗ |
| Target | FANCA | “lentiviral vector carrying the FANCA gene ex vivo” NCT03351868 ↗ |